Search
Diabetes Paid Clinical Trials in Texas
A listing of 90 Diabetes clinical trials in Texas actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 90
The state of Texas currently has 90 active clinical trials seeking participants for Diabetes research studies. These trials are conducted in various cities, including Houston, Dallas, San Antonio and Austin.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Diabetic Peripheral Neuropathy Clinical Study (Raleigh)
Recruiting
If you struggle with chronic nerve pain in your legs due to diabetes (diabetic peripheral neuropathy, or DPN), Vertex Pharmaceuticals is conducting research studies that may be an option.
Conditions:
Diabetic Peripheral Neuropathy
Diabetes
Type 2 Diabetes
Featured Trial
Diabetic Peripheral Neuropathy Clinical Study
Recruiting
If you struggle with chronic nerve pain in your legs due to diabetes (diabetic peripheral neuropathy, or DPN), Vertex Pharmaceuticals is conducting research studies that may be an option.
Conditions:
Diabetes
Diabetes Mellitus
Type 2 Diabetes
Diabetes Mellitus
Type 1
Featured Trial
Diabetic Peripheral Neuropathy Clinical Study
Recruiting
If you struggle with chronic nerve pain in your legs due to diabetes (diabetic peripheral neuropathy, or DPN), Vertex Pharmaceuticals is conducting research studies that may be an option.
Conditions:
Diabetic Peripheral Neuropathy
Diabetes
Type 2 Diabetes
Type 1 Diabetes
Featured Trial
Heart Failure Clinical Trial
Recruiting
You or someone you love may be eligible for a heart failure clinical study. Eligible participants will receive study-related assessments, care, and treatment at no cost. You may be reimbursed for travel while participating. See if you are eligible.
Conditions:
Heart Failure
Congestive Heart Failure
Chronic Heart Failure
Heart Failure
Congestive
Featured Trial
Diabetic Peripheral Neuropathy Clinical Study
Recruiting
If you struggle with chronic nerve pain in your legs due to diabetes (diabetic peripheral neuropathy, or DPN), Vertex Pharmaceuticals is conducting research studies that may be an option.
Conditions:
Diabetes Mellitus
Type 2
Diabetes
Diabetes Mellitus
Type 2 Diabetes
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
Recruiting
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a combination of basal insulin with or without metformin and/or sodium-glucose cotransporter-2 (SGLT2) inhibitor. The study will last about 14 months and may include up to 22 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: Velocity Clinical Research, Dallas, Dallas, Texas +5 locations
Conditions: Type 2 Diabetes
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
Recruiting
The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
07/07/2025
Locations: Texas Childrens Hospital, Houston, Texas
Conditions: Type 2 Diabetes
Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist
Recruiting
This Phase II study is a randomized, parallel group, double blinded, placebo-controlled, multicenter to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and type 2 diabetes on stable GLP-1 RA therapy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/03/2025
Locations: Research Site, San Antonio, Texas
Conditions: Endocrinology, Diabetes, Type II, Obesity
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
Recruiting
TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
07/03/2025
Locations: Hendrick Health, Abilene, Texas +9 locations
Conditions: Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
Recruiting
The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation.
Additionally, long-term follow-up data will also be collected from eligible subjects previously treated in the SPYRAL PIVOTAL-SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: Baylor Jack and Jane Hamilton Heart and Vascular Hospital, Dallas, Texas +5 locations
Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
Description of Patients With Type 1 Diabetes Treated With Teplizumab
Recruiting
Type 1 diabetes mellitus (T1D) is a chronic autoimmune disease caused by the destruction of pancreatic β cells. T1D pathogenesis progresses through several stages: Stage 1 T1D includes the presence of β cell autoimmunity and thus presence of islet autoantibodies, without the presence of dysglycemia and symptoms. Stage 2 T1D includes the presence of islet autoantibodies and dysglycemia, also with no symptoms. Stage 3 T1D includes presence of islet autoantibodies, overt hyperglycemia, and symptoms... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/01/2025
Locations: El Paso Medical Research Institute, El Paso, Texas
Conditions: Type 1 Diabetes
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
Recruiting
The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/01/2025
Locations: Juno Research, Houston, Texas +4 locations
Conditions: Type 2 Diabetes
TrialNet Pathway to Prevention of T1D
Recruiting
Rationale:
The accrual of data from the laboratory and from epidemiologic and prevention trials has improved the understanding of the etiology and pathogenesis of type 1 diabetes mellitus (T1DM). Genetic and immunologic factors play a key role in the development of T1DM, and characterization of the early metabolic abnormalities in T1DM is steadily increasing. However, information regarding the natural history of T1DM remains incomplete. The TrialNet Natural History Study of the Development of T... Read More
Gender:
ALL
Ages:
Between 2 years and 45 years
Trial Updated:
06/30/2025
Locations: University of Texas Medical Center at Dallas, Dallas, Texas +1 locations
Conditions: Diabetes Mellitus, Type 1
Registry for Stage 2 Type 1 Diabetes
Recruiting
Stage 2 Type 1 Diabates (T1D) is an early stage of T1D characterized by dysglycemia but not yet leading to clinical symptoms. Progression of the disease to Stage 3 (clinical T1D), leads to overt hyperglycemia requiring eventually exogenous insulin.
TZIELD® (teplizumab-mzwv) has been approved to delay onset of stage 3 T1D, by the United States (US) Food and Drug Administration (FDA) for adults and children aged 8 years and older with Stage 2 T1D.
The purpose of this study is to collect general... Read More
Gender:
ALL
Ages:
All
Trial Updated:
06/30/2025
Locations: University of Texas - Southwestern Medical Center- Site Number : 8400003, Dallas, Texas +1 locations
Conditions: Type 1 Diabetes
Dapagliflozin Plus Pioglitazone in T1DM
Recruiting
Purpose: To examine the effect of addition of combination therapy with dapagliflozin plus pioglitazone to insulin on glucose control and plasma ketone concentration in patients with type 1 diabetes (T1DM) Research Design: 120 patients with type 1 diabetes who otherwise are healthy constitute the study population. After screening, eligible subjects will start 4 week run in. At week 4, subjects will receive dapagliflozin for 12 weeks. At week 16, subjects will be randomized to receive in a double... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: University Health System Texas Diabetic Institute, San Antonio, Texas
Conditions: Type 1 Diabetes Mellitus
A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
Recruiting
The objective of DIAGNODE-3 is to evaluate the efficacy and safety of three intranodal injections of 4 μg of Diamyd compared to placebo, along with oral Vitamin D supplementation, to preserve endogenous beta cell function and influence glycemic parameters in adolescent and adults recently diagnosed with T1D carrying the HLA DR3-DQ2 haplotype.
Gender:
ALL
Ages:
Between 12 years and 28 years
Trial Updated:
06/26/2025
Locations: Amarillo Medical Specialists, Amarillo, Texas +1 locations
Conditions: Type 1 Diabetes Mellitus
SGLTi, Hepatic Glucose Production and Ketogenesis
Recruiting
In this study, we will test the hypothesis that distinct mechanisms account for the SGLT2i-induced stimulation of ketogenesis and lipolysis versus endogenous (hepatic) glucose production in patients with type 2 diabetes (T2D) and type 1 diabetes (T1D), and that the increases in ketone production and lipolysis can be prevented by concomitant administration of the thiazolidinedione pioglitazone. We will conduct five distinct experiments to test this hypothesis in patients with T2D and T1D.
MAIN S... Read More
Gender:
ALL
Ages:
Between 30 years and 75 years
Trial Updated:
06/26/2025
Locations: Texas Diabetes Institute/UH, San Antonio, Texas
Conditions: Type 2 Diabetes
1 - 12 of 90